Title: Infliximab for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated
Meta-Analysis of Randomized Controlled Trials
Version: 1 Date: 15 May 2025
Reviewer's report:
Infliximab for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Meta-
Analysis of Randomized Controlled Trials
This manuscript presents a well-conducted review and meta-analysis evaluating the efficacy of
infliximab in patients with moderate to severely active ulcerative colitis (UC). The study adheres
to PRISMA guidelines and addresses a clinically relevant research question. A comprehensive
search strategy was employed across multiple databases, and the methodological rigor, that
included subgroup analysis, sensitivity analysis, and meta-regression, strengthens the validity of
the findings. The results are clearly presented, supported by appropriate forest and funnel plots.
Additionally, the authors have adequately addressed all concerns raised by previous reviewers.
However, some minor revisions are needed to further enhance the manuscript.
1. The current abstract lacks a concise background. Abstract should briefly contextualize
the study before stating its aim. L 18–19 (Background: A comprehensive meta-analysis was
performed...) state the aim rather than the background. Clarify the clinical relevance of this
analysis by providing background and aim. In addition, explicitly highlight the implications of
this meta-analysis. Currently, there is no clear implication of the meta-analysis.
2. L 61: Replace "mucous" (adjective) with "mucus" (noun).
3. Lines 86–106: Specify whether only English and Chinese studies were included. If so, state
this under inclusion/exclusion criteria and discuss potential language bias as a limitation (L 427–
447).
4. L 333: Replace "so" with "thus" for formal tone.
5. Address potential biases introduced by excluding non-English studies in the limitations
section (L 427–447).
Title: Infliximab for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated
Meta-Analysis of Randomized Controlled Trials
Version: 1 Date: 15 May 2025
Reviewer's report:
Infliximab for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Meta-
Analysis of Randomized Controlled Trials
This manuscript presents a well-conducted review and meta-analysis evaluating the efficacy of
infliximab in patients with moderate to severely active ulcerative colitis (UC). The study adheres
to PRISMA guidelines and addresses a clinically relevant research question. A comprehensive
search strategy was employed across multiple databases, and the methodological rigor, that
included subgroup analysis, sensitivity analysis, and meta-regression, strengthens the validity of
the findings. The results are clearly presented, supported by appropriate forest and funnel plots.
Additionally, the authors have adequately addressed all concerns raised by previous reviewers.
However, some minor revisions are needed to further enhance the manuscript.
1. The current abstract lacks a concise background. Abstract should briefly contextualize
the study before stating its aim. L 18–19 (Background: A comprehensive meta-analysis was
performed...) state the aim rather than the background. Clarify the clinical relevance of this
analysis by providing background and aim. In addition, explicitly highlight the implications of
this meta-analysis. Currently, there is no clear implication of the meta-analysis.
2. L 61: Replace "mucous" (adjective) with "mucus" (noun).
3. Lines 86–106: Specify whether only English and Chinese studies were included. If so, state
this under inclusion/exclusion criteria and discuss potential language bias as a limitation (L 427–
447).
4. L 333: Replace "so" with "thus" for formal tone.
5. Address potential biases introduced by excluding non-English studies in the limitations
section (L 427–447).
Please review this paper.
user
Title: Infliximab for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated
Meta-Analysis of Randomized Controlled Trials
Version: 1 Date: 15 May 2025
Reviewer's report:
Infliximab for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Meta-
Analysis of Randomized Controlled Trials
This manuscript presents a well-conducted review and meta-analysis evaluating the efficacy of
infliximab in patients with moderate to severely active ulcerative colitis (UC). The study adheres
to PRISMA guidelines and addresses a clinically relevant research question. A comprehensive
search strategy was employed across multiple databases, and the methodological rigor, that
included subgroup analysis, sensitivity analysis, and meta-regression, strengthens the validity of
the findings. The results are clearly presented, supported by appropriate forest and funnel plots.
Additionally, the authors have adequately addressed all concerns raised by previous reviewers.
However, some minor revisions are needed to further enhance the manuscript.
1. The current abstract lacks a concise background. Abstract should briefly contextualize
the study before stating its aim. L 18–19 (Background: A comprehensive meta-analysis was
performed...) state the aim rather than the background. Clarify the clinical relevance of this
analysis by providing background and aim. In addition, explicitly highlight the implications of
this meta-analysis. Currently, there is no clear implication of the meta-analysis.
2. L 61: Replace "mucous" (adjective) with "mucus" (noun).
3. Lines 86–106: Specify whether only English and Chinese studies were included. If so, state
this under inclusion/exclusion criteria and discuss potential language bias as a limitation (L 427–
447).
4. L 333: Replace "so" with "thus" for formal tone.
5. Address potential biases introduced by excluding non-English studies in the limitations
section (L 427–447).
assistant